Detalhe da pesquisa
1.
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
N Engl J Med
; 384(19): 1810-1823, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33979489
2.
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
N Engl J Med
; 373(18): 1733-47, 2015 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26352686
3.
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome.
Ann Hematol
; 95(6): 863-70, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27001309
4.
BRAF mutations in hairy-cell leukemia.
N Engl J Med
; 364(24): 2305-15, 2011 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21663470
5.
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.
Blood
; 119(1): 192-5, 2012 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22028477
6.
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.
Haematologica
; 99(3): 489-96, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24270404
7.
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.
Haematologica
; 99(5): 881-7, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24415628
8.
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
Am J Hematol
; 89(5): 480-6, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24415640
9.
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Am J Hematol
; 88(4): 277-82, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23450508
10.
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Am J Hematol
; 88(11): 955-60, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23861234
11.
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
Br J Haematol
; 156(3): 346-53, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22145911
12.
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naïve chronic lymphocytic leukemia.
Haematologica
; 102(4): e144-e147, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27927769
13.
Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms.
Blood
; 123(17): 2744-5, 2014 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24764562
14.
A proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia.
Eur J Haematol
; 87(3): 228-34, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21595749
15.
Blood smear, a key diagnostic tool in hematology: Lessons from two cases of acute hemolysis in previously undiagnosed G6PD deficiency.
Am J Hematol
; 91(11): 1165-1166, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27074581
16.
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
Am J Hematol
; 86(12): 1007-12, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21953617
17.
Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors.
J Exp Med
; 199(1): 59-68, 2004 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-14707115
18.
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Haematologica
; 100(8): e299-301, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25820333
19.
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients.
Am J Hematol
; 85(7): 494-8, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20575031
20.
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Am J Hematol
; 90(7): E135-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25808917